학술논문
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Document Type
article
Source
European Urology Oncology. 7(3)
Subject
Language